The pivotal STEP trials, which evaluated semaglutide for weight management, did not identify palpitations as a common adverse effect, though individual patient experiences may vary
The next section splits these mechanisms into two practical groups: FDA-approved GLP-1 drugs available only by prescription, such as semaglutide and tirzepatide, and non-prescription peptides that work through growth-hormone stimulation or fat-cell targeting instead, such as CJC-1295 and AOD-9604
Diabetes Obes Metab 16:10871095 Iijima H, Kifuji T, Maruyama N, Inagaki N (2015) Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus
On a GLP-1 medication like semaglutide or tirzepatide, hitting those targets matters more than usual, because eating less overall makes it easy to come up short on protein without noticing